Intel Stock Slides Despite Earnings Beat as Weak Q1 Outlook Raises Concerns 
FSU Criticizes ANZ Over Suncorp Bank Job Cuts Amid Post-Acquisition Commitments 
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors 
Winter Storm Triggers Widespread Flight Cancellations Across U.S. as Airlines Urge Travelers to Rebook 
Tesla Plans FSD Subscription Price Hikes as Autonomous Capabilities Advance 
FCC Chairman Raises Competition Concerns Over Netflix–Warner Bros. Discovery Deal 
BitGo IPO Prices Above Range, Raises $212.8M in Landmark Crypto Market Debut 
NTSB Opens Investigation Into Waymo Robotaxis After School Bus Safety Violations in Texas 
Memory Chip Shortage Drives Higher Gadget Prices and Weakens Global Tech Demand 
Apple China Holiday Sale Offers Discounts Up to 1,000 Yuan on Popular Devices 
Baidu Shares Surge After Official Launch of Advanced Ernie 5.0 AI Model 
Nintendo Stock Jumps as Switch 2 Becomes Best-Selling Console in the U.S. in 2025 
Exxon Mobil’s XTO Energy Explores Sale of Eagle Ford Shale Assets in South Texas 
U.S. Lawmakers Demand Scrutiny of TikTok-ByteDance Deal Amid National Security Concerns 
Goldman Sachs CEO David Solomon’s 2025 Pay Soars to $47 Million After Strong Deal-Making Year 
Toyota Recalls 162,000 Tundra Vehicles in U.S. Over Multimedia Display Issue 
Sanofi Reports Positive Late-Stage Results for Amlitelimab in Eczema Treatment 
SAN DIEGO, May 05, 2017 -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, will announce its financial results for the first quarter ending March 31, 2017, before the market opens on Wednesday, May 10, 2017.
The company will hold a conference call and simultaneous webcast at 8:30 AM Eastern Time (5:30 AM Pacific Time) on Wednesday, May 10, 2017 to discuss the company's financial results and provide a business update. Interested parties may access the conference call by dialing (844) 889-7791 (U.S.) or (661) 378-9934 (international) using passcode 10811814. Media and individuals will be in a listen-only mode. Participants are asked to dial in a few minutes prior to the call to register for the event. The conference call will also be webcast live at: http://edge.media-server.com/m/p/8wft6fu5.
A replay of the call will be available through May 17, 11:30 am ET by calling (855) 859-2056 (U.S.) or (404) 537-3406 (international), using passcode 10811814. An archive of the webcast will be available for twelve months following the event on the Obalon Therapeutics website located at http://investor.obalon.com in the “News & Events” section.
About Obalon Therapeutics, Inc.
Obalon Therapeutics, Inc. (NASDAQ:OBLN) is a San Diego-based company focused on developing and commercializing novel technologies for weight loss. The Obalon management team has over 150 combined years of experience in developing and commercializing novel medical technologies with a track record of financial and clinical excellence. For more information, please visit www.obalon.com.
For Obalon Therapeutics, Inc. Investor Contact: William Plovanic Chief Financial Officer Obalon Therapeutics, Inc. Office: +1 760 607 5103 [email protected] Media: Megan Driscoll EvolveMKD Office Phone: +1 646 517 4220 [email protected]
